Tesamorelin
Egrifta / Egrifta SV / Egrifta WR
- Peptide length
- 44 amino acids
N-terminally modified peptide
Open the sources to check how the studies were done and what they can support.
A stabilized GHRH analog used in a defined FDA-labeled context to reduce excess abdominal fat in adults with HIV and lipodystrophy.
- Family
- GHRH analog
- Research target
- GHRH receptor
- Molecular form
- N-terminally modified peptide
What to know about the research
Read the exact formulation label. Evidence in HIV-associated lipodystrophy is not general weight-loss or anti-aging evidence.
Check the exact compound
Egrifta formulations differ in preparation and delivered dose; they are not automatically substitutable. Confirm the N-terminal modification and formulation.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries